AUTHORS
Yue Wei, PhD, Hong Zheng2, Xiaoping Su, PhD3, Danielle Hammond, MD4, Guillermo Garcia-Manero, MD5
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background: Hematopoietic somatic UBA1 mutations are the defining genetic driver of VEXAS syndrome, a systemic autoinflammatory disease that is frequently associated with myelodysplastic syndromes (MDS). We previously demonstrated that UBA1 RNA expression is reduced in bone marrow (BM) hematopoietic stem and progenitor cells (HSPCs) from patients with MDS and that pharmacologic inhibition of UBA1 induces an MDS-like phenotype in mice. These findings suggest that reduced UBA1 activity may contribute to MDS pathogenesis even in the absence of a pathogenic UBA1 mutation; however, direct genetic evidence remains limited.
Methods and Results: To investigate the role of UBA1 in hematopoiesis, we generated an inducible genetic knockdown model by crossing Uba1flox mice, which contain loxP sites flanking exons 6 and 20, with Vav-Cre or Mx-Cre mice. Hematopoietic Uba1 knock-down resulted in embryonic lethality in Vav-Cre mice and rapid death following poly(I:C) induction in Mx-Cre mice, respectively, supporting an essential role of Uba1 in both embryonic and adult hematopoiesis.
We then established a BM transplantation model. CD45.2+ bone marrow cells from adult Uba1flox/Mx-Cre mice were transplanted into lethally irradiated CD45.1 recipients. Three weeks after transplantation, recipients received weekly poly(I:C) or vehicle treatment, and donor-derived hematopoietic cells were analyzed four weeks after two poly(I:C) doses by flow cytometry and single-cell RNA sequencing (scRNA-seq).
Induced Uba1 knockdown markedly impaired donor hematopoietic repopulation compared with vehicle-treated controls, reducing CD45.2+ cells in total BM (3.18% vs. 66.16%, P<0.01), Gr1+ myeloid cells (1.80% vs. 79.02%, P<0.01), and the Lin−Sca1+c-Kit+ (LSK) compartment (36.28% vs. 70.84%, P<0.05). These effects were not observed in Mx-Cre control donors treated with poly(I:C). Within donor-derived CD45.2+ cells, Uba1 knockdown significantly reduced Gr1+ myeloid cells (16.22% vs. 53.84%, P<0.01), whereas B220+ lymphoid and Ter119+ erythroid populations were unaffected. Common myeloid progenitors (CMPs) and megakaryocyte-erythroid progenitors (MEPs) were also significantly decreased (CMP: 2.12% vs. 16.95%, P<0.01; MEP: 4.43% vs. 24.71%, P<0.05).
scRNA-seq identified 13 hematopoietic cell clusters. Consistent with flow cytometric findings, CMP and granulocyte-monocyte progenitor (GMP) populations were selectively reduced following Uba1 knockdown (CMP: 1.44% vs. 6.90%; GMP: 1.85% vs. 10.38%). To identify Uba1-specific transcriptional changes, genes induced by poly(I:C) in Mx-Cre controls were excluded from differential expression analyses. In the monocytic/macrophage cluster, 195 genes were selectively upregulated following Uba1 knockdown (>1.5-fold, FDR<0.05), with significant enrichment of inflammatory cytokine and interferon signaling pathways. Similar activation of inflammatory pathways was observed in CMP and GMP populations. Notably, six genes were consistently induced across progenitor and mature myeloid populations, including CD64, CD74, and Chil1, established markers of dysregulated BM inflammation and MDS progression.
Conclusions: Genetic knockdown of Uba1 demonstrates that intact Uba1 activity is essential for normal hematopoiesis. Uba1 loss profoundly impaired hematopoietic repopulation and myeloid differentiation while promoting inflammatory cytokine and interferon signaling in progenitor and mature myeloid cells. These findings provide direct genetic evidence that reduced UBA1 activity disrupts hematopoiesis and promotes a proinflammatory bone marrow state, supporting a potential mechanistic role for impaired UBA1 function as a driver of MDS pathogenesis beyond VEXAS-associated disease.
DISCLOSURES
Yue Wei, PhD: No relevant conflicts of interest to declare.